The OTC market has always been an attractive destination for investors seeking to capitalize on the potential of small-cap stocks. With many stocks trading below
ZenaDrone is positioned as one of the beneficiaries of the overall growth trend in the drone market. The Zenadrone 1000 is equipped with machine learning systems, AI technology, and multispectral sensors, making it suitable for use in various industries such as military, agriculture, and oil and gas. Additionally, the drone's ability to generate 3D interactive environment maps from the data collected by its cameras makes it highly versatile across different sectors.
Most recently, EPAZ announced that
Additionally, ZenaDrone has multiple drone demonstrations scheduled, which requires the need for more drones. Last year, ZenaDrone produced 10 ZenaDrone 1000; this year, the goal is to increase production to over 20 drones per month, with the capacity to produce 40 drones in the same facility. This expansion and increased production capacity will allow ZenaDrone to meet its obligations and increase its presence in the drone market.
CEO
The
Investors looking for exposure to the promising military drone market could consider
GTCH's goal is to license this technology and intellectual property to other companies that work in hardware and software. Once their products are ready, they plan to offer a range of products that include smart microchips, AI, encryption, blockchain, IC design, mobile security applications, and database management protocols.
GTCH made a 37.50% jump in price on Thursday, following a press release titled, "GBT's intelligent, human vitals qTerm device patent received an issue notification."
The update detailed that the company has received notice that it will be granted a US patent on
The qTerm device is an intelligent, electronic health device that can measure body temperature, blood oxygen level, and heart rate with just a touch of a finger. This cutting-edge technology has been in development since 2020, and after rigorous testing and debugging, GBT successfully completed a fully working prototype in 2022, which included a participant study.
With this new patent, GBT is set to make a big impact in the healthcare industry and is sure to attract attention from investors looking to get in on the ground floor of this exciting new technology.
On
The decision to accelerate the development of the ARDS programs came in part from a published decision upholding the validity of Patent No. 9,803,176 B2, which covers the composition of matter of JadiCells exclusively licensed to TSOI for lung and brain indications. JadiCells have previously been shown to be 100% effective in COVID-19-induced ARDS patients under 85 years of age.
"The company has stayed a steady course in accomplishing its milestones of in-licensing an advanced cell therapeutic product, filing additional patents surrounding it, demonstrating in animal models and various clinical situations benefits of the product, and now taking the next step in product development by filing for entry into the ARDS patient population, which presents a significantly greater market than COVID-19-induced ARDS", said Dr.
"We are happy to report the decision of our medical advisors to support entry of our adult stem cell-based product into the greater patient population of ARDS", said
This news could make TSOI a potential investment opportunity in the growing field of respiratory distress treatments.
Thursday, SIRC announced that it has reached an agreement with
In exchange for canceling the debt, Granite will receive 4,000,000 shares of common stock. This is a significant achievement in the company's ongoing efforts to reduce its debt and focus on growth, according to
Disclaimers:CapitalGainsReport (CGR) is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. CapitalGainsReport (CGR) is owned by
CONTACT: CapitalGainsReport
Editor
Markrmckelvie@gmail.com
585-301-7700
.
(C) 2023 M2 COMMUNICATIONS, source